M&A: A Strategy for Focused Growth in the Pharmaceutical Industry During Uncertain Times

Big pharma is approaching a perfect storm. As the blockbuster drugs of the past decade drop over the patent cliff, major drug players confront their own shrinking pipelines and increasing scrutiny by the Food and Drug Administration. Small biotech companies developing the next generation of therapeutics are promising growth opportunities. Gerson Lehrman Group convened a panel of experts to discuss the perils and opportunities in the coming wave of pharma consolidation: David Sheehy, Global Lead, Life Sciences Strategy at Accenture, Martyn Postle, Director and Founder of Cambridge Healthcare & Biotech, and David Gryska, former Senior Vice-President and Chief Financial Officer, Celgene. Request Free!